曲伏噻吗(Travoprost/Timolol Maleate) - 药物靶点：PTGFR x β-adrenoceptors_在研适应症：青光眼，开角型青光眼，高眼压症_专利_临床

概要

基本信息

药物类型

小分子化药

别名

DuoTrav APS、DuoTrav BAK、DuoTrav PQ

+ [11]

靶点

PTGFR x β-adrenoceptors

作用机制

PTGFR激动剂(前列腺素FP受体激动剂)、β-adrenoceptors拮抗剂(β-肾上腺素能受体家族拮抗剂)

治疗领域

眼部疾病

在研适应症

青光眼开角型青光眼高眼压症

非在研适应症-

原研机构

Alcon AG

在研机构

Novartis Europharm Ltd.

Novartis Pharmaceuticals Corp.

非在研机构

Alcon Research Ltd.

最高研发阶段批准上市

首次获批日期

欧盟 (2006-04-23),

开角型青光眼高眼压症

最高研发阶段(中国)无进展

特殊审评优先审评 (中国)

登录后查看时间轴

结构

分子式C39H59F3N4O9S

InChIKeyKJNUGXGYVXURJB-DDANCUEQSA-N

CAS号874755-80-3

关联

34

项与曲伏噻吗相关的临床试验

NCT02730871 / Terminated临床4期

Safety and Efficacy With Twice Daily Brinzolamide 1%/Brimonidine 0.2% (SIMBRINZA®) as an Adjunctive Therapy to Travoprost 0.004%/Timolol 0.5% (DUOTRAV®)

The purpose of this study is to evaluate the additive intraocular pressure (IOP) lowering effect of Brinzolamide 1%/Brimonidine 0.2% (SIMBRINZA®) dosed twice daily (BID) when added to Travoprost 0.004%/Timolol 0.5% (DUOTRAV®) in subjects with open-angle glaucoma or ocular hypertension.

开始日期2016-06-24

申办/合作机构

Alcon Research Ltd.

NCT02003391 / Completed临床4期

Prospective, Randomized, Multi-Center Study to Evaluate the Efficacy and Tolerability of DuoTrav® in Patients Previously Uncontrolled on a Beta-blocker

The purpose of this study is to demonstrate superior intraocular pressure (IOP) control with travoprost 0.004% / timolol 0.5% compared to beta-blocker monotherapy in participants with open-angle glaucoma or ocular hypertension.

开始日期2013-12-01

申办/合作机构

Alcon Research Ltd.

NCT01514721 / Terminated临床4期

Assessing the Efficacy and Tolerability of Changing to DuoTrav® (Travoprost 0.004%/Timolol 0.5% BAK-Free Fixed Combination), as Replacement Therapy in Patients Previously on Prior Prostaglandin Fixed Combination

The purpose of this study is to assess efficacy and tolerability of changing to DuoTrav® (Travoprost 0.004%/Timolol 0.5% BAK-free) from prior Xalacom® or Ganfort® fixed combination pharmacotherapy in patients with open-angle glaucoma or ocular hypertension with uncontrolled intraocular pressure (IOP).

开始日期2012-06-01

申办/合作机构

Alcon Research Ltd.

100 项与曲伏噻吗相关的临床结果

登录后查看更多信息

100 项与曲伏噻吗相关的转化医学

登录后查看更多信息

100 项与曲伏噻吗相关的专利（医药）

登录后查看更多信息

69

项与曲伏噻吗相关的文献（医药）

2024-08-01·Vaccine

Single immunization of non-adjuvanted recombinant TTFC-mi3 nanoparticle vaccine elicited a rapid and potent protective immunity against tetanus

Article

作者: Wang, Yi ; Gu, Jiang ; Wu, Meilin ; Wan, Jiqing ; Cheng, Xin ; Luo, Ping ; Chen, Yuan ; He, Qinggang ; Li, Xiaoyan ; Li, Yuhang ; Zhang, Yi

The conventional inactivated tetanus toxin plays an instrumental role in preventing tetanus. Nevertheless, the challenges associated with its production process, the potential for adverse reactions, and reduced effectiveness in vulnerable populations such as neonates and the elderly rise the need for a novel tetanus toxin vaccine. Recombinant subunit vaccine offer a viable solution, and the tetanus toxin fragment C (TTFC) is emerging as a promising candidate. In this study, through spontaneous isopeptide bond formation we conjugated the recombinant TTFC to self-assembled mi3 nanoparticle, which derived from an optimized KDPG aldolase, and generated the TTFC-mi3 protein nanoparticle vaccine. We found that TTFC-mi3 is stable, uniform spherical nanoparticles. Comparing with the free TTFC alone, TTFC-mi3 enhances the uptake and subsequent activation of dendric cells (DCs). In addition, a single dose of adjuvant-free TTFC-mi3 elicited a more rapid and potent protective immunity in mice. Moreover, TTFC-mi3 is of favorable safety in vitro and in vivo. Our findings indicate that TTFC-mi3 is a rapid-response, non-aluminum-adjuvanted vaccine against tetanus.

2022-09-05·Journal of Epidemiology3区 · 医学

Association of the Time to First Cigarette and the Prevalence of Chronic Respiratory Diseases in Chinese Elderly Population

3区 · 医学

ArticleOA

作者: Wang, Chao ; Lou, Yiling ; Cao, Shiyi ; Jiang, Heng ; Lu, Zuxun ; Gan, Yong ; Guo, Yingying ; Tian, Qingfeng ; Zhu, Yi

BACKGROUNDIncreasing number of studies have suggested the time to first cigarette after waking (TTFC) have significant positive effect on respiratory diseases. However, few of them focused on the Chinese population. This study aims to estimate the impact of TTFC on the prevalence of chronic respiratory diseases (CRD) in Chinese elderly and explore the association in different sub-populations.METHODSCross-sectional data of demographic characteristics, living environment, smoking-related variables, and CRD were drawn from the Chinese Longitudinal Healthy Longevity Survey in 2018. Multivariate stepwise logistic regression analyses were conducted to examine the association of the TTFC with the prevalence of CRD.RESULTSThis study includes 13,208 subjects aged 52 years and older, with a mean age of 85.3 years. Of them, 3,779 participants were ex- or current smokers (44.9% had the TTFC ≤30 minutes, 55.1% >30 minutes) and 1,492 had suffered from CRD. Compared with non-smokers, participants with TTFC ≤30 minutes seemed to have higher prevalence of CRD (OR 1.97; 95% CI, 1.65-2.35) than those with TTFC >30 minutes (OR 1.70; 95% CI, 1.44-2.00), although the difference was statistically insignificant (P_interaction = 0.12). Compared with TTFC >30 minutes, TTFC ≤30 minutes could drive a higher prevalence of CRD among female participants, those aged 90 years and older, urban residents, and ex-smokers (P_interaction < 0.05).CONCLUSIONShorter TTFC relates to higher prevalences of CRD in Chinese older females, those aged 90 years and older, urban residents, and ex-smokers. Delaying TTFC might partially reduce its detrimental impact on respiratory disease in these specific subpopulations.

2020-12-01·Microbial Cell Factories2区 · 工程技术

A probiotic treatment increases the immune response induced by the nasal delivery of spore-adsorbed TTFC

2区 · 工程技术

ArticleOA

作者: Mazzoli, Arianna ; Leite, Fabio ; Ricca, Ezio ; Isticato, Rachele ; Baccigalupi, Loredana ; Santos, Francisco Denis S ; Maia, Ana Raquel ; Saggese, Anella ; Iossa, Susanna

AbstractBackgroundSpore-forming bacteria of the Bacillus genus are widely used probiotics known to exert their beneficial effects also through the stimulation of the host immune response. The oral delivery of B. toyonensis spores has been shown to improve the immune response to a parenterally administered viral antigen in mice, suggesting that probiotics may increase the efficiency of systemic vaccines. We used the C fragment of the tetanus toxin (TTFC) as a model antigen to evaluate whether a treatment with B. toyonensis spores affected the immune response to a mucosal antigen.ResultsPurified TTFC was given to mice by the nasal route either as a free protein or adsorbed to B. subtilis spores, a mucosal vaccine delivery system proved effective with several antigens, including TTFC. Spore adsorption was extremely efficient and TTFC was shown to be exposed on the spore surface. Spore-adsorbed TTFC was more efficient than the free antigen in inducing an immune response and the probiotic treatment improved the response, increasing the production of TTFC-specific secretory immunoglobin A (sIgA) and causing a faster production of serum IgG. The analysis of the induced cytokines indicated that also the cellular immune response was increased by the probiotic treatment. A 16S RNA-based analysis of the gut microbial composition did not show dramatic differences due to the probiotic treatment. However, the abundance of members of the Ruminiclostridium 6 genus was found to correlate with the increased immune response of animals immunized with the spore-adsorbed antigen and treated with the probiotic.ConclusionOur results indicate that B. toyonensis spores significantly contribute to the humoral and cellular responses elicited by a mucosal immunization with spore-adsorbed TTFC, pointing to the probiotic treatment as an alternative to the use of adjuvants for mucosal vaccinations.

3

项与曲伏噻吗相关的新闻（医药）

2024-08-14

·米内网

【火热】山东药企入局$20亿明星药首仿

精彩内容日前，CDE官网显示，辰欣药业的布瑞哌唑片以仿制4类报产在审。米内网数据显示，布瑞哌唑在2023年全球销售额突破20亿美元，同比增长超过20%。今年以来，辰欣药业已有20款产品报产在审。来源：米内网项目进度数据库布瑞哌唑是由丹麦灵北制药和日本大冢制药共同研发的一种非典型抗精神病药物，用于治疗重度抑郁症、精神分裂症等。米内网数据显示，布瑞哌唑2023年全球销售额突破20亿美元，同比增长超过20%。今年6月，大冢制药的布瑞哌唑片在中国获批进口，目前国内暂无仿制药企业获批。布瑞哌唑报产在审产品情况来源：米内网中国申报进度（MED）数据库目前，布瑞哌唑报产在审的产品有布瑞哌唑片、布瑞哌唑口溶膜、布瑞哌唑口崩片，其中，布瑞哌唑片竞争最为激烈，有12家企业（28个受理号），其中，辰欣药业和扬子江南京海陵药业在今年8月报产，成都康弘药业集团、重庆药友制药、珍宝岛药业等10家均在今年7月报产。辰欣药业今年以来报产在审产品来源：米内网中国申报进度（MED）数据库今年以来，辰欣药业已有20款产品报产在审，涵盖神经系统药物、呼吸系统用药、全身用抗感染药物等多个治疗大类，其中，布瑞哌唑片、克立硼罗软膏、曲伏噻吗滴眼液冲刺首仿，达肝素钠注射液、复方醋酸钠林格注射液、盐酸溴己新注射液、布洛芬混悬液在2023年中国三大终端六大市场均是10亿元级别的重磅产品。资料来源：CDE官网、米内网数据库注：米内网《中国三大终端六大市场药品竞争格局》，统计范围是：城市公立医院和县级公立医院、城市社区中心和乡镇卫生院、城市实体药店和网上药店，不含民营医院、私人诊所、村卫生室，不含县乡村药店；上述销售额以产品在终端的平均零售价计算。如有疏漏，欢迎指正！本文为原创稿件，转载请注明来源和作者，否则将追究侵权责任。投稿及报料请发邮件到872470254@qq.com稿件要求详询米内微信首页菜单栏商务及内容合作可联系QQ：412539092 【分享、点赞、在看】点一点不失联哦

一致性评价专利侵权

2022-09-06

·GlobeNewswire-Health Care

Eyenovia to Participate in Multiple Medical Meetings in September

NEW YORK, Sept. 06, 2022 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), an ophthalmic pharmaceutical technology company developing a pipeline of late-stage microdose array print (MAP™) therapeutics, today announced that the company will be participating in multiple medical meetings in September. Details of the presentations are as follows: Meeting: Ophthalmology Futures European Forum 2022Title: The Optejet – Advancing Drug Delivery and Improving Patient ExperiencePresenter: Beth Scott, OD, VP, Regulatory and Medical AffairsDate: Thursday, September 15, 2022Location: Principe di Savoia, Milan, Italy Meeting: The T.H.E. Summit by Treehouse EyesTitle: Drug/Device Technology to Improve Pediatric Progressive Myopia TreatmentPresenter: Michael Rowe, Chief Executive OfficerDate: September 15, 2022Location: Caesars, Las Vegas, NV Meeting: 40th Congress of the European Society of Cataract and Refractive Surgeons (ESCRS) 2022Title: In Vitro Cell Toxicity Comparing Microdose vs Drop Delivery of Latanoprost with BAK in Human Conjunctival CellsPresenter: Pedram Hamrah, MD, FACS, Department of Ophthalmology, Tufts Medical CenterDate: September 16-20, 2022Format: ePoster presentation, accessible for the duration of the conferenceLocation: Milano Convention Centre, Milan, Italy Meeting: Eyecelerator at AAO 2022Title: The Optejet® | The First and Only Human-Centric Ophthalmic Topical Medication DevicePresenter: Michael Rowe, Chief Executive OfficerDate: Thursday, September 29, 2022Location: McCormick Place, Chicago, Il About Eyenovia, Inc.Eyenovia, Inc. (NASDAQ: EYEN) is an ophthalmic pharmaceutical technology company developing a pipeline of microdose array print (MAPTM) therapeutics. Eyenovia is currently focused on the late-stage development of microdosed medications for mydriasis, presbyopia and myopia progression. For more information, visit Eyenovia.com. The Eyenovia Corporate Information slide deck may be found at ir.eyenovia.com/events-and-presentations. Forward-Looking StatementsExcept for historical information, all of the statements, expectations and assumptions contained in this press release are forward-looking statements. Forward-looking statements include, but are not limited to, statements that express our intentions, beliefs, expectations, strategies, predictions or any other statements relating to our future activities or other future events or conditions, including estimated market opportunities for our product candidates and platform technology. These statements are based on current expectations, estimates and projections about our business based, in part, on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Therefore, actual outcomes and results may, and in some cases are likely to, differ materially from what is expressed or forecasted in the forward-looking statements due to numerous factors discussed from time to time in documents which we file with the U.S. Securities and Exchange Commission. In addition, such statements could be affected by risks and uncertainties related to, among other things: risks of our clinical trials, including, but not limited to, the costs, design, initiation and enrollment (which could still be adversely impacted by COVID-19 and resulting social distancing), timing, progress and results of such trials; the timing of, and our ability to submit applications for, obtaining and maintaining regulatory approvals for our product candidates; the potential impacts of COVID-19 on our supply chain; the potential advantages of our product candidates and platform technology; the rate and degree of market acceptance and clinical utility of our product candidates; our estimates regarding the potential market opportunity for our product candidates; reliance on third parties to develop and commercialize our product candidates; the ability of us and our partners to timely develop, implement and maintain manufacturing, commercialization and marketing capabilities and strategies for our product candidates; intellectual property risks; changes in legal, regulatory and legislative environments in the markets in which we operate and the impact of these changes on our ability to obtain regulatory approval for our products; and our competitive position. Any forward-looking statements speak only as of the date on which they are made, and except as may be required under applicable securities laws, Eyenovia does not undertake any obligation to update any forward-looking statements. Eyenovia Contact:Eyenovia, Inc.John GandolfoChief Financial Officerjgandolfo@eyenovia.com Eyenovia Investor Contact:Eric RibnerLifeSci Advisors, LLCeric@lifesciadvisors.com(646) 751-4363 Eyenovia Media Contact:Eyenovia, Inc.Norbert LoweVice President, Commercial Operationsnlowe@eyenovia.com

2022-09-06

·BioSpace

Eyenovia to Participate in Multiple Medical Meetings in September 2022

NEW YORK, Sept. 06, 2022 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), an ophthalmic pharmaceutical technology company developing a pipeline of late-stage microdose array print (MAP™) therapeutics, today announced that the company will be participating in multiple medical meetings in September. Details of the presentations are as follows: Meeting: Ophthalmology Futures European Forum 2022 Title: The Optejet – Advancing Drug Delivery and Improving Patient Experience Presenter: Beth Scott, OD, VP, Regulatory and Medical Affairs Date: Thursday, September 15, 2022 Location: Principe di Savoia, Milan, Italy Meeting: The T.H.E. Summit by Treehouse Eyes Title: Drug/Device Technology to Improve Pediatric Progressive Myopia Treatment Presenter: Michael Rowe, Chief Executive Officer Date: September 15, 2022 Location: Caesars, Las Vegas, NV Meeting: 40th Congress of the European Society of Cataract and Refractive Surgeons (ESCRS) 2022 Title: In Vitro Cell Toxicity Comparing Microdose vs Drop Delivery of Latanoprost with BAK in Human Conjunctival Cells Presenter: Pedram Hamrah, MD, FACS, Department of Ophthalmology, Tufts Medical Center Date: September 16-20, 2022 Format: ePoster presentation, accessible for the duration of the conference Location: Milano Convention Centre, Milan, Italy Meeting: Eyecelerator at AAO 2022 Title: The Optejet® | The First and Only Human-Centric Ophthalmic Topical Medication Device Presenter: Michael Rowe, Chief Executive Officer Date: Thursday, September 29, 2022 Location: McCormick Place, Chicago, Il About Eyenovia, Inc. Eyenovia, Inc. (NASDAQ: EYEN) is an ophthalmic pharmaceutical technology company developing a pipeline of microdose array print (MAPTM) therapeutics. Eyenovia is currently focused on the late-stage development of microdosed medications for mydriasis, presbyopia and myopia progression. For more information, visit Eyenovia.com. The Eyenovia Corporate Information slide deck may be found at ir.eyenovia.com/events-and-presentations. Forward-Looking Statements Except for historical information, all of the statements, expectations and assumptions contained in this press release are forward-looking statements. Forward-looking statements include, but are not limited to, statements that express our intentions, beliefs, expectations, strategies, predictions or any other statements relating to our future activities or other future events or conditions, including estimated market opportunities for our product candidates and platform technology. These statements are based on current expectations, estimates and projections about our business based, in part, on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Therefore, actual outcomes and results may, and in some cases are likely to, differ materially from what is expressed or forecasted in the forward-looking statements due to numerous factors discussed from time to time in documents which we the U.S. Securities and Exchange Commission. In addition, such statements could be affected by risks and uncertainties related to, among other things: risks of our clinical trials, including, but not limited to, the costs, design, initiation and enrollment (which could still be adversely impacted by COVID-19 and resulting social distancing), timing, progress and results of such trials; the timing of, and our ability to submit applications for, obtaining and maintaining regulatory approvals for our product candidates; the potential impacts of COVID-19 on our supply chain; the potential advantages of our product candidates and platform technology; the rate and degree of market acceptance and clinical utility of our product candidates; our estimates regarding the potential market opportunity for our product candidates; reliance on third parties to develop and commercialize our product candidates; the ability of us and our partners to timely develop, implement and maintain manufacturing, commercialization and marketing capabilities and strategies for our product candidates; intellectual property risks; changes in legal, regulatory and legislative environments in the markets in which we operate and the impact of these changes on our ability to obtain regulatory approval for our products; and our competitive position. Any forward-looking statements speak only as of the date on which they are made, and except as may be required under applicable securities laws, Eyenovia does not undertake any obligation to update any forward-looking statements. Eyenovia Contact: Eyenovia, Inc. John Gandolfo Chief Financial Officer jgandolfo@eyenovia.com Eyenovia Investor Contact: Eric Ribner LifeSci Advisors, LLC eric@lifesciadvisors.com (646) 751-4363 Eyenovia Media Contact: Eyenovia, Inc. Norbert Lowe Vice President, Commercial Operations nlowe@eyenovia.com

100 项与曲伏噻吗相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	-	S01ED51	-

研发状态

批准上市

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
青光眼	日本	Novartis Pharmaceuticals Corp.	2010-04-16
开角型青光眼	欧盟	Novartis Europharm Ltd.	2006-04-23
开角型青光眼	列支敦士登	Novartis Europharm Ltd.	2006-04-23
开角型青光眼	冰岛	Novartis Europharm Ltd.	2006-04-23
开角型青光眼	挪威	Novartis Europharm Ltd.	2006-04-23
高眼压症	列支敦士登	Novartis Europharm Ltd.	2006-04-23
高眼压症	冰岛	Novartis Europharm Ltd.	2006-04-23
高眼压症	挪威	Novartis Europharm Ltd.	2006-04-23
高眼压症	欧盟	Novartis Europharm Ltd.	2006-04-23

未上市

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
开角型青光眼	临床2期	美国	Alcon Research Ltd.	2007-03-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


ARVO2019	N/A	青光眼	152	Xalacom	(憲膚夢窪蓋夢壓蓋淵鹹) = 醖範餘齋衊餘艱鑰製糧範餘憲膚鹽淵鹹簾膚憲 (鹽齋艱憲窪繭積壓願範 )	-	2019-07-01
				Duo Trav	(憲膚夢窪蓋夢壓蓋淵鹹) = 醖觸獵壓齋鬱簾餘艱製範餘憲膚鹽淵鹹簾膚憲 (鹽齋艱憲窪繭積壓願範 )
NCT02730871 (CTgov)	临床4期	开角型青光眼	173	Brinzolamide 1%/brimonidine tartrate 0.2% ophthalmic suspension+Travoprost 0.004%/timolol 0.5% solution (Simbrinza + Duotrav)	選壓襯築齋獵膚鏇蓋鬱(糧艱壓繭糧鬱觸壓簾餘) = 遞齋醖顧糧選鑰蓋簾簾襯願網鹽積範醖窪膚顧 (夢餘鏇艱築鑰繭鑰壓淵, 淵築淵衊鹽觸淵齋壓糧 ~ 襯淵膚艱獵艱遞構製範) 更多	-	2019-05-17
				Brinzolamide/brimonidine vehicle+Travoprost 0.004%/timolol 0.5% solution (Vehicle + Duotrav)	選壓襯築齋獵膚鏇蓋鬱(糧艱壓繭糧鬱觸壓簾餘) = 餘繭襯醖製願鏇顧獵網襯願網鹽積範醖窪膚顧 (夢餘鏇艱築鑰繭鑰壓淵, 範構遞築鬱選憲遞窪願 ~ 艱鬱鹽衊憲醖憲廠網蓋) 更多
NCT02003391 (CTgov)	临床4期	开角型青光眼	157	Travoprost 0.004% / timolol 0.5% fixed combination ophthalmic solution (DuoTrav)	遞願積願顧選獵鏇蓋鏇(齋繭築淵窪遞範顧蓋廠) = 鑰網鑰夢蓋觸夢衊願糧艱網繭醖廠顧窪構鏇構 (餘遞鹹艱鏇鹹積網網鹹, 獵網範遞鏇壓蓋壓鏇鬱 ~ 獵顧膚窪鏇衊蓋壓襯壓) 更多	-	2016-08-08
				Beta-blocker monotherapy+Travoprost 0.004% / timolol 0.5% fixed combination ophthalmic solution (Beta-blocker)	遞願積願顧選獵鏇蓋鏇(齋繭築淵窪遞範顧蓋廠) = 醖選簾襯壓網觸鏇糧繭艱網繭醖廠顧窪構鏇構 (餘遞鹹艱鏇鹹積網網鹹, 淵鬱艱觸蓋鏇鹹鏇鬱蓋 ~ 顧鬱獵築鹽鏇鏇網鬱製) 更多
NCT01547598 (CTgov)	临床4期	开角型青光眼	135	Bimatoprost ophthalmic solution 0.01%+travoprost ophthalmic solution 0.004% (LUMIGAN® RC)	願壓選窪廠醖遞選鹹壓(網憲鹹糧築蓋觸觸鏇鏇) = 選蓋艱餘窪醖獵窪範鹹網範醖鬱蓋築範壓範壓 (製壓觸選鏇淵願願網選, 觸廠顧觸夢選窪範鏇選 ~ 膚廠夢壓構淵遞窪鹹範) 更多	-	2014-08-15
				travoprost ophthalmic solution 0.004%+travoprost 0.004% / timolol 0.5% combination ophthalmic solution (DuoTrav®)	願壓選窪廠醖遞選鹹壓(網憲鹹糧築蓋觸觸鏇鏇) = 艱齋網淵網餘醖窪鑰鏇網範醖鬱蓋築範壓範壓 (製壓觸選鏇淵願願網選, 遞鏇淵鹽製襯簾顧積憲 ~ 積製襯醖淵膚顧艱製糧) 更多
NCT01327599 (CTgov)	临床4期	青光眼相关色素分散综合征	60	Travoprost 0.004%+Timolol 0.5% ophthalmic solution	選獵遞鹹夢選鬱憲夢願(衊醖壓膚觸構獵廠繭蓋) = 範選製廠願廠選構遞鬱範製願壓顧衊襯廠網構 (鹹壓壓夢觸網選餘製願, 願糧齋糧獵網夢膚獵鬱 ~ 鹽觸觸顧選憲製範鑰築) 更多	-	2014-01-10
NCT01336569 (CTgov)	临床4期	开角型青光眼	50	Travoprost 0.004%/timolol maleate 0.5% fixed combination	製顧蓋廠餘積製鬱構糧(顧夢獵齋繭壓遞鏇繭網) = 鹹糧窪夢鑰遞艱簾鹽窪遞構鏇製願鑰範齋鹹鹹 (鏇廠積衊齋願繭膚醖鏇, 窪淵壓築窪鏇繭簾築獵 ~ 窪鹹觸選餘齋廠遞觸簾) 更多	-	2013-07-08
NCT00508469 (CTgov)	临床4期	开角型青光眼	102	Travalert Dosing Aid+Travoprost 0.004%/timolol 0.5% fixed combination eye drops (DuoTrav) (Travalert With Travoprost/Timolol Fixed Combination)	膚簾衊齋壓膚憲鏇膚網(衊艱網廠獵鹹製構顧壓) = 窪廠鏇簾鬱鏇願築夢鹽遞醖範製獵夢糧廠範遞 (繭構襯餘願鏇鏇醖觸簾, 遞衊醖築觸築憲網齋網 ~ 廠製艱鏇憲願範鏇鏇壓) 更多	-	2012-07-12
				Travalert Dosing Aid+Timolol 0.05% eye drops+Travoprost 0.004% eye drops (Travalert With Travoprost and Timolol)	膚簾衊齋壓膚憲鏇膚網(衊艱網廠獵鹹製構顧壓) = 鑰願觸憲壓構鹹選鏇鹽遞醖範製獵夢糧廠範遞 (繭構襯餘願鏇鏇醖觸簾, 淵選廠築鏇鬱選繭廠網 ~ 鏇壓遞廠夢網製鑰襯淵) 更多
ARVO2010	N/A	青光眼	45	Travoprost/timolol	醖壓艱淵選網遞衊製窪(構觸壓糧範鏇獵遞襯觸) = 鬱艱獵鑰簾願製範簾簾醖鹹廠鹹窪夢襯鏇衊衊 (夢範網鑰鏇窪憲鬱壓壓 ) 更多	-	2010-04-01
				Glaucoma patients treated with bimatoprost/timolol	醖壓艱淵選網遞衊製窪(構觸壓糧範鏇獵遞襯觸) = 顧鏇築齋網淵膚製淵鹽醖鹹廠鹹窪夢襯鏇衊衊 (夢範網鑰鏇窪憲鬱壓壓 ) 更多
NCT00444184 (ARVO2008)	临床4期	开角型青光眼	34	Travoprost/Timolol Fixed Combination	(獵鬱餘構夢膚選憲窪鏇) = 壓鏇鏇壓觸齋鏇鹹鑰憲顧襯膚壓願壓衊願蓋淵 (餘鬱獵願鏇遞齋網鑰構 )	积极	2008-05-01
				Travoprost	(獵鬱餘構夢膚選憲窪鏇) = 齋繭鹹鬱鹹製積淵齋鹽顧襯膚壓願壓衊願蓋淵 (餘鬱獵願鏇遞齋網鑰構 )
ARVO2006	N/A	-	-	Travoprost 0.004%/Timolol 0.5% Ophthalmic Solution	(淵淵觸糧廠鹹顧壓築憲) = 製願鹽網廠範衊製廠艱獵淵鹽鬱鹹淵糧鏇鹹鹹 (簾廠鬱簾簾餘夢鏇餘艱 )	-	2006-05-01
				Xalatan and Timolol 0.5%	(淵淵觸糧廠鹹顧壓築憲) = 夢廠顧觸願壓糧膚蓋製獵淵鹽鬱鹹淵糧鏇鹹鹹 (簾廠鬱簾簾餘夢鏇餘艱 )